4D Molecular Therapeutics, Inc. (FDMT), a biotechnology company, Monday announced that it has appointed Kristian Humer as its new chief financial officer.
Humer will be replacing Uneek Mehra, who stepped down from his role in July this year.
Humer has more than two decades of experience spanning corporate finance, strategic operations and healthcare investment banking and was the Managing Director in Citi's Healthcare Investment Banking Group. He was also the finance chief of publicly traded companies including Foghorn Therapeutics, Inc. and Viridian Therapeutics, Inc.
On Friday, FDMT shares closed at $10.79, up 4.96% on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.